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CORRESPONDENCE
Letters to the Editor
Predicting the Effectiveness
of Beta-Blocker Therapy
in Vasovagal Syncope
There has been a great deal of interest in the therapeutic role of
beta-adrenergic blockade in patients suffering from vasovagal
syncope. The efficacy of beta-blockers in these patients may be due
to blunting of elevated catecholamine levels that precede vasovagal
syncope (1). Notwithstanding the widespread use of beta-blockers
in the past, some studies on chronic beta-blocker use have been less
than encouraging and may suggest some benefit in older but not in
younger patients, as mentioned in the recent article by Tan and
Parry (2). That being said, might there be a better way to predict
the favorable use of beta-blocker therapy in patients suffering from
vasovagal syncope? In one study of patients with confirmed
vasovagal syncope, all patients with a negative tilt test response
during esmolol infusion had a negative tilt test response with oral
metoprolol. Of the remaining patients with a positive tilt test
response during esmolol infusion, 90% continued to have a positive
response with oral metoprolol (3). In another study, a negative test
with esmolol infusion among 112 patients with vasovagal syncope
was again found to be an independent predictor for prevention of
symptoms with oral metoprolol during follow-up of 2.7  1.2
years (p  0.0001) (4). Those authors concluded that “acute
challenge with esmolol infusion appears to be an accurate predictor
of response to chronic beta-blockers.” A negative head-up tilt test
during propanolol infusion was similarly found to predict favorable
responses to oral beta-blocker therapy in other studies, including a
prospective trial of 296 patients (5–7). Thus, data on the effec-
tiveness of a beta-blocker challenge during the head-up tilt test in
patients with vasovagal syncope may be very helpful in formulating
a therapeutic strategy.
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Reply
We thank Dr. Kapoor for his interest in our recent paper (1). As
mentioned by Dr. Kapoor, beta-blockers had indeed found wide-
spread usage in the treatment of vasovagal syncope in the past.
Earlier uncontrolled studies (2,3) and 1 small randomized-
controlled study (4) had demonstrated encouraging results, fueling
this practice. However, recent randomized controlled trials (5,6),
as well as the only multicenter, randomized, placebo-controlled
trial published to date (7), have failed to demonstrate any beneficial
effects with beta-blockers. There was a statistically nonsignificant
trend to benefit in the subgroup of subjects 42 years of age,
suggesting that further evaluation of the use of beta-blockers in
older subjects may be warranted (8).
The studies cited by Dr. Kapoor were uncontrolled studies
evaluating the role of intravenous beta-blockers in predicting
treatment response to long-term oral beta-blocker therapy. Fol-
lowing the positive diagnosis of vasovagal syncope with a head-up
tilt (HUT) test, a second HUT was performed to assess response
to intravenous esmolol or propanolol (9–11). However, there has
been a reasonable body of evidence demonstrating that the
reproducibility of a positive HUT is low (12–15). The role of
HUT as an instrument to evaluate treatment benefit is therefore
limited, and can only be used in this context if a comparison is
made with placebo (16).
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